androgen deprivation


Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.
Related to androgen deprivation: Androgen Deprivation Therapy

androgen deprivation

1. The chemical suppression of male sex hormones to prevent their stimulatory effects on various hormone-sensitive illnesses, including prostate cancer and predatory sexual behavior. Synonym: androgen suppression
2. Orchiectomy.
See also: deprivation
References in periodicals archive ?
Vaishampayan noted that all men who are diagnosed with metastatic, hormone-sensitive prostate cancer on androgen deprivation become castrate-resistant within a median of 18-24 months after their initial diagnosis.
Increased risk of metabolic syndrome, diabetes mellitus, and cardiovascular disease in men receiving androgen deprivation therapy for prostate cancer.
73) The increased expression, greater stability, and nuclear localization of AR in recurrent prostate cancers resistant to androgen deprivation correlated with hypersensitivity to low levels of androgens in these tumors; androgen ablation-resistant prostate cancers required a significantly much lower concentration of dihydrotestosterone than that required by androgen-dependent tumors for stimulation of proliferative activity.
Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.
GTx is developing ACAPODENE([R]) (toremifene citrate), a selective estrogen receptor modulator, or SERM, in two separate clinical programs in men: first, a pivotal Phase III clinical trial evaluating toremifene citrate 80 mg for the treatment of serious side effects of androgen deprivation therapy for advanced prostate cancer, and second, a pivotal Phase III clinical trial evaluating toremifene citrate 20 mg for the prevention of prostate cancer in high risk men with high grade prostatic intraepithelial neoplasia, or PIN.
Addition of radiotherapy to long-term androgen deprivation in locally advanced prostate cancer: An open randomised phase 3 trial.
1 "Toremifene citrate increases bone mineral density in men receiving androgen deprivation therapy for prostate cancer.
There is a clear, unmet medical need for new treatment options for prostate cancer patients, especially those with castration-resistant prostate cancer who often become resistant to androgen deprivation therapy," commented Dr.
06 and VCOG PR 01-03: The Timing Of Androgen Deprivation Therapy In Prostate Cancer Patients With A Rising PSA (TOAD) Collaborative Randomised Phase III Trial examined 293 patients with PSA relapse after definitive therapy to compare if immediate ADT versus delayed ADT affected OS.
One group of researchers found that primary androgen deprivation therapy fails to improve either overall or disease-specific survival in this patient population, yet it still is widely used as the initial treatment for localized disease.
TSE: 4503) announced final results on the primary and secondary efficacy endpoints from the Phase 3 PREVAIL trial of enzalutamide in patients with chemotherapy-naE[macron]ve metastatic prostate cancer who have failed androgen deprivation therapy and have few or no symptoms.
Androgen deprivation therapy is highly effective; however, the tumour eventually becomes resistant to the treatment and regrows in an incurable form.

Full browser ?